Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers
- 1Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea
- 2Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea
- 3Center for Clinical Trial, Hospital, National Cancer Center, Goyang, Republic of Korea
- 4Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea
- 5Rare and Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea
- 6Department of Cancer Control and Policy, National Cancer Center, Goyang, Republic of Korea
by Kim SH, Kim KH, Hyun JW, Kim JH, Seo SS, Kim HJ, Park SY and Lim MC (2022) Front. Oncol. 12:942960. doi: 10.3389/fonc.2022.942960
In the published article, acknowledgement was mistakenly not included in the publication. The missing material appears below:
“Preoperative blood samples from 32 study participants with gynecological cancer were provided by the National Cancer Center (NCC) Biobank.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: paclitaxel, neuropathy, neurofilament light (NfL), gynecological cancer, chemotherapy induced peripheral neuropathy
Citation: Kim S-H, Kim KH, Hyun J-W, Kim JH, Seo S-S, Kim HJ, Park S-Y and Lim MC (2023) Corrigendum: Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. Front. Oncol. 13:1279558. doi: 10.3389/fonc.2023.1279558
Received: 21 August 2023; Accepted: 21 August 2023;
Published: 07 September 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Kim, Kim, Hyun, Kim, Seo, Kim, Park and Lim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Myong Cheol Lim, mclim@ncc.re.kr; gynlim@gmail.com